

January 31, 2022

Company Name HEALIOS K.K.  
Representative Hardy TS Kagimoto, Chairman & CEO  
(TSE Mothers Code: 4593)

## Announcement of Change in Management

HEALIOS K.K. (“Healios”) announces the following change in management.

### 1) Change of Executive Officer

Name	Current Position	Former position	Date of change
Koichi Tamura	Executive Officer, in charge of research / Head of Kobe Research Institute	Executive Officer, in charge of research and manufacturing / Head of Kobe Research Institute	February 1, 2022

### 2) Appointment of new Executive Officer

Name	Current Position	Former position	Date of change
Junichi Kotera	Executive Officer, in charge of manufacturing	Expert Manufacturing Division	February 1, 2022

#### • Reason of the appointment

The newly appointed Executive Officer, Junichi Kotera, has over 30 years of experience in manufacturing at pharmaceutical companies. He joined Healios in 2017 and has served as the General Manager of the Manufacturing Department of Sighregen Co., Ltd., a joint venture between Healios and Sumitomo Dainippon Pharma Co., Ltd., and the General Manager of the Manufacturing Division of Healios. Prior to that, he set up new manufacturing facilities for Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.) in the United States and Ireland, and he has managed and supervised production sites as the factory manager of Astellas Takaoka Factory (currently Astellas Pharma Tec Co., Ltd.). He has also served as a factory manager and executive officer at GlaxoSmithKline plc. With his wealth of experience in pharmaceutical product manufacturing both in Japan and overseas, we have determined that Mr. Kotera is well-suited for managing the manufacturing area at Healios.

Contact  
Department of Corporate Communications, HEALIOS K.K.  
Mail: [ir@healios.jp](mailto:ir@healios.jp)